Pure Global AI
NCT06214143Recruiting

A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors

A Single-arm, Multi-center Phase Ib/IIa Clinical Study to Evaluate the Tolerability, Safety, and Initial Efficacy of T3011 Herpesvirus Injection Combined With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., LtdPhase 1/2ClinicalTrials.govbiological
Verified
Study focus
Disease/Condition
Advanced Solid Tumors
Drug/Device/Intervention
T3011 high dose
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Location
Anyang,Bengbu,Changsha,Chengdu,Dongwan,Fuzhou,Guangzhou,Guangzhou,Ha'erbin,Hangzhou,Hangzhou,Jinan,Nanchang,Nanning,Shanghai,Shanghai,Shenyang,Shenzhen,Taiyuan,Tianjin,Wuhan,Zhengzhou, China
Timeline & enrollment
Phase
Phase 1/2
Start date
Jan 11, 2024
End date
May 31, 2026
Enrollment
68 participants
Primary outcome

Incidence of Treatment-Emergent Adverse Events,Objective response rate(ORR)

Summary

This clinical study evaluated the efficacy and safety of T3011 in combination with PD-1/PD-L1
 inhibitors in subjects with advanced solid tumors

ICD-10 classifications
Malignant neoplasm: PrepuceCarcinoma in situ, unspecifiedMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm: Orbit
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06214143
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06214143 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Shanghai Pharmaceuticals Holding Co., Ltd and is currently Recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 68 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.